This trial is testing a new treatment for multiple myeloma that uses the patient's own T cells that have been modified to express a γδTCR. The study will assess the safety and efficacy of this treatment in a small group of patients.
2 Primary · 11 Secondary · Reporting Duration: until Year 2
26 Total Participants · 1 Treatment Group
Primary Treatment: TEG002 · No Placebo Group · Phase 1
Age 18+ · All Participants · 9 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: